AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 JAN 23 - (NewsRx.com & NewsRx.net) -- BioSante Pharmaceuticals, Inc., announced results of a preclinical trial demonstrating the effectiveness of its calcium phosphate nanoparticulate (CAP) delivery system for the administration of drugs into the eye.
The results were presented December 20, 2001, at the sixth U.S.-Japan Symposium on Drug Delivery in Hawaii, cosponsored by the Massachusetts Institute of Technology, Kyoto University, Controlled Release Society, Inc., and the Japanese Society of Drug Delivery Systems.
In the study, a dopamine D3 receptor agonist, known as 7-hydroxy-dipropyl-aminotetralin (7-OH-DPAT), was combined with CAP in a proprietary formulation prepared by scientists at BioSante's research center in Smyrna, Georgia, and therapeutic efficacy was tested in two types of rabbits. The study was designed to test the effects of CAP on the ability of 7-OH-DPAT to decrease intraocular pressure (IOP), a major risk factor of glaucoma in humans.
Results showed that the addition of CAP to 7-OH-DPAT resulted in significant extension of the IOP lowering effect of the drug in New Zealand White rabbits, compared to the same amount of drug without CAP. In Dutch Belted rabbits, which have pigmented eyes, the ...